C₁₇H₂₀N₄S (P274)
Quantities
| P4250 | defined daily dose | 10 |
| P2067 | mass | 312.1409 |
| P3780 | active ingredient in | ... | Q29006251 (Olansek) | Olansek |
| P3780 | active ingredient in | ... | Q29006252 (Olanzapine Apotex) | Olanzapine Apotex |
| P3780 | active ingredient in | ... | Q29006254 (Olanzapine Cipla) | Olanzapine Cipla |
| P3780 | active ingredient in | ... | Q29006255 (Olanzapine Glenmark) | Olanzapine Glenmark |
| P3780 | active ingredient in | ... | Q29006257 (Olanzapine Glenmark Europe) | Olanzapine Glenmark Europe |
| P3780 | active ingredient in | ... | Q29006258 (Olanzapine Mylan) | Olanzapine Mylan |
| P3780 | active ingredient in | ... | Q29006259 (Olanzapine Teva) | Olanzapine Teva |
| P3780 | active ingredient in | ... | Q29006261 (Olazax) | Olazax |
| P3780 | active ingredient in | ... | Q29006262 (Olazax Disperzi) | Olazax Disperzi |
| P3780 | active ingredient in | ... | Q29006712 (Zalasta) | Zalasta |
| P3780 | active ingredient in | ... | Q29006767 (Zyprexa) | Zyprexa |
| P3780 | active ingredient in | ... | Q29006768 (Zyprexa Velotab) | Zyprexa Velotab |
| P233 | canonical SMILES | String | CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C | ??? |
| P373 | Commons category | String | Olanzapine | ??? |
| P527 | has part(s) | ... | Q627 (nitrogen) | nitrogen |
| P527 | has part(s) | ... | Q623 (carbon) | carbon |
| P366 | has use | ... | Q12140 (medication) | medication |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P2175 | medical condition treated | ... | Q41112 (schizophrenia) | schizophrenia |
| P2175 | medical condition treated | ... | Q12135 (mental disorder) | mental disorder |
| P2175 | medical condition treated | ... | Q83030 (dementia) | dementia |
| P2175 | medical condition treated | ... | Q154430 (anxiety) | anxiety |
| P2175 | medical condition treated | ... | Q131755 (bipolar disorder) | bipolar disorder |
| P2175 | medical condition treated | ... | Q178190 (obsessive-compulsive disorder) | obsessive-compulsive disorder |
| P2175 | medical condition treated | ... | Q188638 (mood disorder) | mood disorder |
| P2175 | medical condition treated | ... | Q170082 (psychosis) | psychosis |
| P2175 | medical condition treated | ... | Q834047 (schizoaffective disorder) | schizoaffective disorder |
| P2175 | medical condition treated | ... | Q1869874 (insomnia) | insomnia |
| P2175 | medical condition treated | ... | Q2157462 (schizophreniform disorder) | schizophreniform disorder |
| P2175 | medical condition treated | ... | Q54972453 (sleep-wake disorder) | sleep-wake disorder |
| P2175 | medical condition treated | ... | Q544006 (anxiety disorder) | anxiety disorder |
| P361 | part of | ... | Q22274447 (response to olanzapine) | response to olanzapine |
| P129 | physically interacts with | ... | Q288797 (5-hydroxytryptamine receptor 1B) | 5-hydroxytryptamine receptor 1B |
| P129 | physically interacts with | ... | Q309513 (Histamine receptor H1) | Histamine receptor H1 |
| P129 | physically interacts with | ... | Q1949517 (5-hydroxytryptamine receptor 2A) | 5-hydroxytryptamine receptor 2A |
| P129 | physically interacts with | ... | Q2034004 (Dopamine receptor D2) | Dopamine receptor D2 |
| P129 | physically interacts with | ... | Q21108118 (5-hydroxytryptamine receptor 2C) | 5-hydroxytryptamine receptor 2C |
| P129 | physically interacts with | ... | Q21109355 (5-hydroxytryptamine receptor 7) | 5-hydroxytryptamine receptor 7 |
| P129 | physically interacts with | ... | Q21109363 (5-hydroxytryptamine receptor 6) | 5-hydroxytryptamine receptor 6 |
| P129 | physically interacts with | ... | Q21115043 (5-hydroxytryptamine receptor 1A) | 5-hydroxytryptamine receptor 1A |
| P129 | physically interacts with | ... | Q21115046 (5-hydroxytryptamine receptor 1D) | 5-hydroxytryptamine receptor 1D |
| P129 | physically interacts with | ... | Q21115051 (5-hydroxytryptamine receptor 1E) | 5-hydroxytryptamine receptor 1E |
| P129 | physically interacts with | ... | Q21115052 (5-hydroxytryptamine receptor 1F) | 5-hydroxytryptamine receptor 1F |
| P3489 | pregnancy category | ... | Q3679261 (Australian pregnancy category C) | Australian pregnancy category C |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P769 | significant drug interaction | ... | Q55434 (pethidine) | pethidine |
| P769 | significant drug interaction | ... | Q144085 (pimozide) | pimozide |
| P769 | significant drug interaction | ... | Q58614 (loxapine) | loxapine |
| P769 | significant drug interaction | ... | Q81225 (morphine) | morphine |
| P769 | significant drug interaction | ... | Q174723 (codeine) | codeine |
| P769 | significant drug interaction | ... | Q176533 (alfentanil) | alfentanil |
| P769 | significant drug interaction | ... | Q221361 (clozapine) | clozapine |
| P769 | significant drug interaction | ... | Q179996 ((RS)-methadone) | (RS)-methadone |
| P769 | significant drug interaction | ... | Q300989 (levodopa) | levodopa |
| P769 | significant drug interaction | ... | Q303646 (hydromorphone) | hydromorphone |
| P769 | significant drug interaction | ... | Q409761 (amantadine) | amantadine |
| P769 | significant drug interaction | ... | Q411188 (aripiprazole) | aripiprazole |
| P769 | significant drug interaction | ... | Q377270 (dihydrocodeine) | dihydrocodeine |
| P769 | significant drug interaction | ... | Q407535 (oxycodone) | oxycodone |
| P769 | significant drug interaction | ... | Q407541 (fentanyl) | fentanyl |
| P769 | significant drug interaction | ... | Q2622907 (periciazine) | periciazine |
| P769 | significant drug interaction | ... | Q228143 (zuclopenthixol) | zuclopenthixol |
| P769 | significant drug interaction | ... | Q251347 (haloperidol) | haloperidol |
| P769 | significant drug interaction | ... | Q412221 (clonidine) | clonidine |
| P769 | significant drug interaction | ... | Q413591 (sotalol) | sotalol |
| P769 | significant drug interaction | ... | Q414463 (tapentadol) | tapentadol |
| P769 | significant drug interaction | ... | Q417915 (sufentanil) | sufentanil |
| P769 | significant drug interaction | ... | Q421937 ((RS)-hydroxyzine) | (RS)-hydroxyzine |
| P769 | significant drug interaction | ... | Q422418 ((RS)-sulpiride) | (RS)-sulpiride |
| P769 | significant drug interaction | ... | Q407592 (tramadol) | tramadol |
| P769 | significant drug interaction | ... | Q407721 (buprenorphine) | buprenorphine |
| P769 | significant drug interaction | ... | Q408535 (quetiapine) | quetiapine |
| P9989 | stylized name | String | OLANZapine | ??? |
| P9989 | stylized name | String | ZyPREXA | ??? |
| P279 | subclass of | ... | Q193430 (heterocyclic compound) | heterocyclic compound |
| P279 | subclass of | ... | Q758295 (atypical antipsychotic) | atypical antipsychotic |
| P2868 | subject has role | ... | Q208144 (antipsychotics) | antipsychotics |
| P2868 | subject has role | ... | Q334477 (selective serotonin reuptake inhibitor) | selective serotonin reuptake inhibitor |
| P2868 | subject has role | ... | Q1328275 (H1 antagonist) | H1 antagonist |
| P2868 | subject has role | ... | Q3001265 (muscarinic antagonist) | muscarinic antagonist |
| P2868 | subject has role | ... | Q1927838 (alpha blocker) | alpha blocker |
| P2868 | subject has role | ... | Q3271533 (dopamine antagonist) | dopamine antagonist |
| P2868 | subject has role | ... | Q7455047 (serotonin antagonist) | serotonin antagonist |
| P2868 | subject has role | ... | Q575136 (antiemetic) | antiemetic |
| P2868 | subject has role | ... | Q816759 (beta blocker) | beta blocker |
| P6185 | tautomer of | ... | Q106042109 (olanzapine tautomer) | olanzapine tautomer |
Why not click here or view trends?
log id: None